Send me a link:

*Text messaging rates may apply.

 Dow Down0.72% Nasdaq Down0.50%

More On RVX.TO

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Resverlogix Corp. (RVX.TO)

-Toronto
0.78 Up 0.02(2.63%) Jul 25
ProfileGet Profile for:
Resverlogix Corp.
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada - Map
Phone: 403-254-9252
Fax: 403-256-8495
Website: http://www.resverlogix.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:40

Business Summary 

Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Resverlogix Corp.

Key Executives 
 PayExercised
Mr. Donald J. McCaffrey ,
Co-Founder, Chief Exec. Officer, Pres, Sec. and Director
561.00K0.00
Mr. Aaron Brad Cann C.A., CBV,
Chief Financial Officer
310.00K0.00
Dr. Norman C. W. Wong B.Sc (Hon), M.Sc, M.D., FRCP,
Co-Founder, Chairman of the Scientific Advisory Board and Chief Scientific Officer
N/AN/A
Dr. Henrik C. Hansen ,
VP of Intellectual Property & Technology Devel.
N/AN/A
Sarah Zapotichny ,
Director of Investor Relations
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.